Literature DB >> 16280701

A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic.

Elizabeth Y Chiao1, Susan E Krown, Elizabeth A Stier, Deborah Schrag.   

Abstract

Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence is increased among the immunosuppressed. We used data from the Surveillance, Epidemiology, and End Results program to analyze the incidence of SCCA in relation to 3 separate periods during the HIV epidemic: the pre-HIV era (1973-1981), the HIV era (1982-1995), and the highly active antiretroviral treatment (HAART) era (1996-2001). The incidence per 100,000 population of SCCA increased from 0.6 in the pre-HIV era to 0.8 in the HIV era and to 1.0 in the HAART era. The gap in SCCA incidence between women and men decreased from a ratio of 1.6:1 in the pre-HIV era to 1.5:1 in the HIV era and to 1.2:1 in the HAART era. There was a significant increase in incidence rates among men and women aged 30 to 54 years in the HAART era compared with the HIV era. Men were more likely to be diagnosed with early-stage disease, but they were less likely than women to receive radiation therapy. The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART.

Entities:  

Mesh:

Year:  2005        PMID: 16280701     DOI: 10.1097/01.qai.0000159669.80207.12

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

1.  Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.

Authors:  Danielle S Bitterman; David Grew; Ping Gu; Richard F Cohen; Nicholas J Sanfilippo; Cynthia G Leichman; Lawrence P Leichman; Harvey G Moore; Heather T Gold; Kevin L Du
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 2.  Basic Science, Epidemiology, and Screening for Anal Intraepithelial Neoplasia and Its Relationship to Anal Squamous Cell Cancer.

Authors:  Kurt G Davis; Guy R Orangio
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

3.  Description of a pilot anal pap smear screening program among individuals attending a Veteran's Affairs HIV clinic.

Authors:  Isabella Rosa-Cunha; Vincent A Degennaro; Rene Hartmann; Clara Milikowski; Andres Irizarry; Brenda Heitman; Orlando Gómez-Marín; Gordon M Dickinson
Journal:  AIDS Patient Care STDS       Date:  2011-03-02       Impact factor: 5.078

4.  The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection.

Authors:  Luis F Barroso
Journal:  Ther Adv Vaccines       Date:  2013-07

5.  Risk of Invasive Anal Cancer in HIV-Infected Patients With High-Grade Anal Dysplasia: A Population-Based Cohort Study.

Authors:  Yotam Arens; Michael Gaisa; Stephen E Goldstone; Yuxin Liu; Juan Wisnivesky; Carlie S Sigel; Talia H Swartz; Keith Sigel
Journal:  Dis Colon Rectum       Date:  2019-08       Impact factor: 4.585

6.  Anal squamous cell carcinoma in the HIV-positive patient.

Authors:  Deborah Nagle
Journal:  Clin Colon Rectal Surg       Date:  2009-05

7.  The association between body mass index and anal canal human papillomavirus prevalence and persistence: the HIM study.

Authors:  Alan G Nyitray; Fen Peng; Rena S Day; Roberto J Carvalho Da Silva; Maria Luiza Baggio; Jorge Salmerón; Manuel Quiterio; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Anna R Giuliano
Journal:  Hum Vaccin Immunother       Date:  2019-04-19       Impact factor: 3.452

8.  Uncertainty Abounds in the World of Anal Dysplasia Screening.

Authors:  Wesley G Willeford; Laura H Bachmann
Journal:  Sex Transm Dis       Date:  2016-07       Impact factor: 2.830

9.  Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco.

Authors:  Alexandra L Hernandez; Jimmy T Efird; Elizabeth A Holly; J Michael Berry; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Anal dysplasia screening: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2007-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.